NeuroMetrix, Inc. (NURO) to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
11/27/2012 3:31:16 PM
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology & Diagnostics Forum at the Le Parker Meridien, New York, NY on December 4, 2012. Dr. Gozani intends to provide an update on the Company’s business activities and on its diabetes products including NC-stat® DPNCheck™, a diagnostic test for systemic neuropathies such as diabetic peripheral neuropathy (DPN), and the SENSUS™ pain management device for relief of chronic intractable pain.
comments powered by